Ulta Mandel

Title: Ulta Mandel: Innovator in Cancer Detection

Introduction

Ulta Mandel is a pioneering inventor based in Holte, Denmark. She has made significant contributions to the field of cancer detection through her innovative research and development. Her work focuses on utilizing biomarkers for the early detection of cancer, which holds great promise for improving patient outcomes.

Latest Patents

Ulta Mandel holds a patent for a method for early detection of cancer. This invention demonstrates that circulating auto-antibodies to cancer antigens can serve as specific and sensitive biomarkers for early cancer detection. The method involves detecting cancer in a sample by utilizing a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. The antibodies detected are glycopeptide specific, allowing for differentiation between colorectal cancer patients and healthy individuals. Additionally, the inventors have developed monoclonal antibodies based on the identified glycopeptides epitope baits, showcasing differential expression of relevant target antigens. This invention includes both glycopeptides and antibody tools for early cancer detection, as well as methods for in situ visualization and treatment of specific cancer types. Ulta Mandel has 1 patent to her name.

Career Highlights

Ulta Mandel is associated with Go Therapeutics, Inc., where she continues her groundbreaking work in cancer research. Her career is marked by a commitment to advancing medical science and improving diagnostic methods for cancer.

Collaborations

Ulta has collaborated with notable colleagues, including Hans H Wandall and Johannes W Pedersen, who share her dedication to cancer research and innovation.

Conclusion

Ulta Mandel's contributions to cancer detection through her innovative patent highlight her role as a significant figure in the field. Her work not only advances scientific understanding but also has the potential to save lives through early detection methods.